

Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Stock Quote


ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$6.90
Change (%)	- 0.15 (2.13%)
Volume	243,550

Data as of July 20, 2018 4:00 p.m. ET

Minimum 20 minute delay

[Refresh quote](#)

Stock Chart



Press Releases

June 07, 2018

[Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab](#)

May 10, 2018

[Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference](#)

Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters